Moderna forecasts lower sales next year, shares near four-year low

Sep 12, 2024 · Moderna forecasts lower sales next year, shares near four-year low. By ... The forecast also accounted for Moderna's prediction that each of the 10 new products it expects …

$1
OFF

Moderna Forecasts Lower Sales Next Year, Shares Near Four-year Low

2 weeks from now

Sep 12, 2024 · Moderna forecasts lower sales next year, shares near four-year low Its cost savings would include a cut of $1.1 billion from research and development from 2026, with …

indiatimes.com

$9
OFF

Moderna: Fair Value Cut Following Lower 2025 Sales ... - Morningstar

2 weeks from now

1 day ago · Moderna ended 2024 with $9.5 billion in cash but had a burn rate of $4 billion in 2024. With planned cost controls, we assume Moderna can conserve enough cash to avoid dilution …

morningstar.com

$1
OFF

Moderna's $1 Billion Revenue Forecast Cut Sends Stock

2 weeks from now

2 days ago · Moderna shares plunged Monday after the company cut its 2025 revenue forecast by $1 billion. ... second half of the year” in large part from sales of its Covid-19 and respiratory …

investopedia.com

$1
OFF

Moderna Cuts 2025 Sales Forecast By $1 Bln On Weak Vaccine …

2 weeks from now

2 days ago · Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending …

reuters.com

$2
OFF

Shares Of Vacine Maker Moderna Slide To Four-year Low - RTÉ

2 weeks from now

Sep 12, 2024 · The vaccine maker expects sales between $2.5 billion and $3.5 billion next year, below analysts' forecast of $3.74 billion, according to LSEG data. The midpoint was also …

rte.ie

$1
OFF

Moderna Cuts Sales Forecast On Weaker Vaccine Demand - Yahoo …

2 weeks from now

2 days ago · Moderna cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine. The company now expects …

yahoo.com

17%
OFF

Moderna Stock Plunges Nearly 17% After Company Lowers 2025 …

2 weeks from now

He said Moderna's share of the U.S. retail market for Covid shots fell to 40% at the end of 2024 from 48% in 2023, and the company is preparing for another decline this year.

msn.com

94%
OFF

Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?

2 weeks from now

1 day ago · Sales expectations for Moderna have come down markedly over the last year. ... Moderna shares also have a low ... to reduce its costs by $1 billion this year and $500 million …

investors.com

17%
OFF

Vaccine Maker Moderna Sees Sales Fall Next Year, Shares Fall 17% To ...

2 weeks from now

Sep 12, 2024 · Shares of the vaccine maker were down 17.1% to $65.88 at midday. Moderna on Thursday pushed back its breakeven target by two years after it slowed development timelines …

businessinvestopedia.com

FAQs about Moderna forecasts lower sales next year, shares near four-year low Coupon?

Why did Moderna cut its 2025 sales forecast?

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 24% in early trading. ...

Why did Moderna shares drop 22 per cent on Monday?

Moderna shares dropped as much as 22 per cent on Monday after the US biotech group’s sales forecasts disappointed investors. The Boston-based company projected sales this year of $1.5bn-$2.5bn, down from a previous forecast of $2.5bn-$3.5bn and lower than some analyst estimates for $2.4bn-$2.9bn. ...

Why did Moderna stock fall 22%?

By Connor Hart Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.07 in late morning trading Monday. ...

How much will Moderna sell in 2026?

(Reuters) - Moderna on Thursday said it expects sales of between $2.5 billion and $3.5 billion next year, and forecast that new product launches would drive an average annual growth rate of 25% in revenue between 2026 and 2028. ...

Why did Moderna's shares tumble in early trading Monday?

(AP Photo/Eugene Hoshiko, File) Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year. Moderna said it expects 2025 revenue to range between $1.5 billion and $2.5 billion after hitting as much as $3.1 billion last year. ...

Did Moderna generate minimal sales in the year?

The company said that generated minimal sales in the year. Moderna made its announcement Monday ahead of a presentation at the annual J.P. Morgan Healthcare Conference in San Fransisco. The company will detail its fourth-quarter results on Feb. 14. ...